Table 3.
Crude and adjusted linear regression models of predictors of mean change and percent change in weight and hypertension at 12-months among patients on HIV treatment at the Themba Lethu Clinic in Johannesburg South Africa (n = 1588).
| Crude mean change in weight∗ (95% CI) |
Adjusted mean change in weight∗ (95% CI) | Crude percent change in weight∗ (95% CI) |
Adjusted percent change in weight∗ (95% CI) | Crude hypertension (RD; 95% CI) |
Adjusted hypertension (RD; 95% CI) |
|
|---|---|---|---|---|---|---|
| Exposed | ||||||
| efavirenz | ref. | ref. | ref. | ref. | ref. | ref. |
| dolutegravir | 1.34 (0.75, 1.93) | 1.78 (1.04, 2.52) | 2.31 (1.31, 3.31) | 2.90 (1.63, 4.17) | 14.4 (10.6, 18.1) | 14.2 (10.6, 17.7) |
| Age at ART initiation (years) | ||||||
| 16–24.9 | −0.10 (−1.22, 1.02) | 0.77 (−0.37, 1.91) | 0.36 (−1.54, 2.26) | 1.43 (−0.52, 3.39) | −23.1 (−30.1, −16.1) | −14.2 (−21.2, −7.19) |
| 25–29.9 | 0.92 (−0.46, 2.30) | 1.08 (−0.29, 2.44) | 1.24 (−1.10, 3.59) | 1.25 (−1.11, 3.60) | −22.1 (−30.8, −13.4) | −15.0 (−23.4, −6.55) |
| 30–39.9 | 0.54 (−0.39–1.47) | 0.61 (−0.30, 1.52) | 0.57 (−1.01, 2.15) | 0.65 (−0.91, 2.22) | −14.4 (−20.3, −8.60) | −9.61 (−15.2, −4.00) |
| 40–49.9 | 0.69 (−0.26, 1.63) | 0.69 (−0.23, 1.61) | 1.06 (−0.54, 2.66) | 1.06 (−0.52, 2.64) | −6.03 (−12.0, −0.11) | −3.30 (−8.96, 2.37) |
| ≥50 | ref. | ref. | ref. | ref. | ref. | ref. |
| CD4 Category (cells/mm3) | ||||||
| <200 | ref. | ref. | ref. | ref. | ref. | ref. |
| 200–299 | −0.20 (−1.55, 1.15) | −0.27 (−1.59, 1.06) | −0.67 (−2.96, 1.61) | −0.60 (−2.87, 1.67) | 5.82 (−2.80, 14.4) | 6.83 (−1.32, 15.0) |
| 300–399 | −0.30 (−1.62, 1.02) | −0.70 (−2.00, 0.60) | −0.96 (−3.20, 1.28) | −1.36 (−3.61, 0.88) | 1.49 (−6.94, 9.92) | 2.67 (−5.39, 10.7) |
| 400–499 | −0.96 (−2.30, 0.37) | −0.92 (−2.24, 0.41) | −1.29 (−3.55, 0.98) | −1.09 (−3.36, 1.19) | 5.41 (−3.13, 14.0) | 7.51 (−0.66, 15.7) |
| ≥500 | −0.76 (−1.96, 0.43) | −0.94 (−2.14, 0.27) | −1.40 (−3.42, 0.63) | −1.52 (−3.59, 0.55) | 0.83 (−6.78, 8.45) | 3.84 (−3.60, 11.3) |
| Viral load suppression (<1000 copies/mL) | ||||||
| Yes | ref. | ref. | ref. | ref. | ref. | ref. |
| No | 0.18 (−3.12, 3.47) | −0.19 (−3.42, 3.03) | −0.61 (−6.19, 4.98) | −1.16 (−3.71, 4.39) | −10.5 (−31.6, 10.5) | −1.21 (−21.1, 18.6) |
| Haemoglobin (ug/dL) | ||||||
| ≥10.0 | ref. | ref. | ref. | ref. | ref. | ref. |
| <10.0 | −1.71 (−4.10, 0.67) | −1.18 (−3.52, 1.16) | −2.70 (−6.74, 1.34) | −2.19 (−6.22, 1.84) | −6.23 (−21.5, 9.00) | −0.56 (−15.0, 13.9) |
| Sex | ||||||
| Male | ref. | ref. | ref. | ref. | ref. | ref. |
| Female | 0.87 (0.28, 1.46) | 0.16 (−0.46, 0.78) | 1.22 (0.21, 2.21) | 0.42 (−0.65, 1.49) | −5.03 (−9.03, −1.15) | −3.96 (−7.80, −0.12) |
| Nucleoside reverse transcriptase inhibitor | ||||||
| Lamivudine | ref. | ref. | ref. | ref. | ref. | ref. |
| Emtricitabine | −0.74 (−1.41, −0.08) | −0.30 (−1.11, 0.51) | −0.83 (−1.96, 0.30) | −0.01 (−1.40, 1.39) | 0.67 (−3.59, 4.92) | 0.12 (−4.87, 5.11) |
| Time on ART (months) | ||||||
| 0–11.9 | 2.65 (1.66, 3.65) | 2.32 (1.23, 3.41) | 4.20 (2.51, 5.89) | 3.98 (2.11, 5.86) | −0.36 (−6.79, 6.08) | 3.25 (−3.48, 9.98) |
| 12–23.9 | 0.51 (−0.31, 1.32) | 0.07 (−0.86, 1.00) | 0.53 (−0.86, 1.91) | 0.24 (−1.36, 1.84) | −2.12 (−7.39, 3.14) | 1.05 (−4.69, 6.78) |
| 24–35.9 | −0.04 (−1.00, 0.92) | −0.06 (−1.08, 0.95) | 0.02 (−1.60, 1.65) | 0.14 (−1.61, 1.89) | −1.20 (−7.38, 4.97) | 2.65 (−3.63, 8.93) |
| 36–47.9 | 0.19 (−0.88, 1.26) | 0.06 (−1.07, 1.20) | 0.38 (−1.44, 2.21) | 0.42 (−1.54, 2.37) | −2.57 (−9.51, 4.36) | −2.46 (−9.49, 4.57) |
| 48–59.9 | −0.08 (−1.18, 1.03) | −0.18 (−1.34, 0.99) | −0.33 (−2.21, 1.54) | −0.26 (−2.27, 1.75) | 2.22 (−4.91, 9.36) | 2.05 (−5.17, 9.26) |
| ≥60 | ref. | ref. | ref. | ref. | ref. | ref. |
| Body Mass Index (kg/m2) | ||||||
| <18.5 | 1.23 (−0.54, 3.00) | 1.08 (−0.68, 2.83) | 2.74 (−0.30, 5.77) | 2.48 (−0.54, 5.51) | 2.20 (−9.33, 13.7) | 3.34 (−7.52, 14.2) |
| 18.5–24.9 | 2.84 (1.05, 4.63) | 2.86 (1.08–4.65) | 4.94 (1.87, 8.01) | 4.94 (1.87, 8.02) | 11.7 (0.03, 23.3) | 9.78 (−1.24, 20.8) |
| 25–29.9 | 4.22 (2.44, 5.99) | 4.27 (2.48, 6.06) | 6.08 (3.04, 9.12) | 6.13 (3.04, 9.21) | 9.61 (−1.94, 21.2) | 8.20 (−2.87, 19.3) |
| ≥30.0 | ref. | ref. | ref. | ref. | ref. | ref. |
| Hypertension | ||||||
| No | ref. | ref. | ref. | ref. | ref. | ref. |
| Yes | −0.87 (−1.67, −0.06) | −1.03 (−1.83, 0.24) | −1.13 (−2.49, 0.22) | −1.33 (−2.70, 0.04) | 30.7 (25.8, 35.6) | 26.8 (21.9, 31.7) |
∗
Models for the mean change and weight and percent change in weight are also adjusted for continuous days between date of baseline weight and time of switch and days between follow-up weight and 12-months. For the outcome of hypertension, the complete list of variables in the table were controlled for in the model.